Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Urinary Bladder Neoplasms | 78 | 2024 | 2223 | 10.660 |
Why?
|
Cystectomy | 45 | 2024 | 634 | 8.070 |
Why?
|
Prostatic Neoplasms | 119 | 2024 | 11118 | 6.480 |
Why?
|
Carcinoma, Transitional Cell | 15 | 2023 | 782 | 3.250 |
Why?
|
Androgen Antagonists | 31 | 2024 | 1410 | 3.220 |
Why?
|
Radiation Oncology | 15 | 2022 | 563 | 2.890 |
Why?
|
Urinary Bladder | 23 | 2023 | 1152 | 2.030 |
Why?
|
Radiotherapy, Intensity-Modulated | 16 | 2021 | 801 | 2.020 |
Why?
|
Neoplasm Invasiveness | 39 | 2024 | 3595 | 1.930 |
Why?
|
Prostatectomy | 22 | 2024 | 1824 | 1.740 |
Why?
|
Seminoma | 6 | 2023 | 134 | 1.690 |
Why?
|
Prostate-Specific Antigen | 29 | 2024 | 2469 | 1.600 |
Why?
|
Antineoplastic Agents, Hormonal | 10 | 2020 | 1520 | 1.580 |
Why?
|
Salvage Therapy | 15 | 2024 | 1264 | 1.530 |
Why?
|
Watchful Waiting | 6 | 2023 | 491 | 1.520 |
Why?
|
Photons | 4 | 2021 | 589 | 1.510 |
Why?
|
Radiotherapy, Adjuvant | 15 | 2018 | 1784 | 1.430 |
Why?
|
Radiotherapy | 17 | 2022 | 1499 | 1.380 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 17 | 2023 | 1661 | 1.370 |
Why?
|
Urethral Neoplasms | 4 | 2017 | 37 | 1.350 |
Why?
|
Combined Modality Therapy | 31 | 2024 | 8529 | 1.330 |
Why?
|
Testicular Neoplasms | 7 | 2023 | 799 | 1.310 |
Why?
|
Neoplasm Recurrence, Local | 23 | 2024 | 9280 | 1.200 |
Why?
|
Goserelin | 4 | 2015 | 126 | 1.110 |
Why?
|
Chemotherapy, Adjuvant | 14 | 2021 | 3514 | 1.090 |
Why?
|
Radiotherapy Dosage | 27 | 2023 | 2898 | 1.070 |
Why?
|
Muscles | 11 | 2023 | 1576 | 1.000 |
Why?
|
Male | 180 | 2024 | 360804 | 0.890 |
Why?
|
Neoplasm Staging | 32 | 2024 | 11121 | 0.890 |
Why?
|
Brachytherapy | 11 | 2020 | 1223 | 0.880 |
Why?
|
Muscle Neoplasms | 3 | 2018 | 130 | 0.820 |
Why?
|
Adenocarcinoma | 11 | 2023 | 6346 | 0.820 |
Why?
|
Humans | 255 | 2024 | 761504 | 0.810 |
Why?
|
Hospitals, General | 3 | 2017 | 798 | 0.800 |
Why?
|
Medical Oncology | 6 | 2020 | 2321 | 0.800 |
Why?
|
Flutamide | 2 | 2015 | 95 | 0.790 |
Why?
|
Radiotherapy, Conformal | 9 | 2018 | 548 | 0.770 |
Why?
|
Organs at Risk | 7 | 2021 | 359 | 0.750 |
Why?
|
BCG Vaccine | 5 | 2024 | 369 | 0.730 |
Why?
|
Disease-Free Survival | 20 | 2024 | 6814 | 0.720 |
Why?
|
Carcinoma | 6 | 2017 | 2330 | 0.720 |
Why?
|
Kaplan-Meier Estimate | 14 | 2020 | 6484 | 0.680 |
Why?
|
Lymph Nodes | 6 | 2023 | 3466 | 0.680 |
Why?
|
Treatment Outcome | 58 | 2023 | 64680 | 0.670 |
Why?
|
Aged | 83 | 2024 | 169289 | 0.650 |
Why?
|
Neoadjuvant Therapy | 11 | 2023 | 2827 | 0.640 |
Why?
|
Urologic Surgical Procedures | 3 | 2018 | 298 | 0.630 |
Why?
|
Rectum | 11 | 2021 | 892 | 0.620 |
Why?
|
Orchiectomy | 3 | 2023 | 463 | 0.600 |
Why?
|
Insurance Coverage | 4 | 2022 | 1940 | 0.600 |
Why?
|
Quality of Life | 20 | 2024 | 13367 | 0.590 |
Why?
|
Paclitaxel | 2 | 2023 | 1732 | 0.580 |
Why?
|
Proportional Hazards Models | 18 | 2024 | 12463 | 0.580 |
Why?
|
Urothelium | 2 | 2016 | 269 | 0.570 |
Why?
|
Neoplasms | 16 | 2022 | 22170 | 0.560 |
Why?
|
X-Ray Therapy | 1 | 2016 | 8 | 0.560 |
Why?
|
Protons | 6 | 2021 | 1116 | 0.540 |
Why?
|
Leuprolide | 2 | 2015 | 312 | 0.540 |
Why?
|
Personal Autonomy | 1 | 2018 | 304 | 0.530 |
Why?
|
Carcinoma, Squamous Cell | 6 | 2017 | 4026 | 0.520 |
Why?
|
Developing Countries | 4 | 2015 | 2885 | 0.510 |
Why?
|
Botswana | 12 | 2024 | 1048 | 0.510 |
Why?
|
Healthcare Disparities | 6 | 2022 | 3358 | 0.500 |
Why?
|
Paintings | 1 | 2016 | 103 | 0.490 |
Why?
|
Prostate | 10 | 2024 | 1770 | 0.490 |
Why?
|
Middle Aged | 77 | 2024 | 220895 | 0.490 |
Why?
|
Cancer Care Facilities | 3 | 2015 | 422 | 0.490 |
Why?
|
Urethra | 3 | 2018 | 405 | 0.480 |
Why?
|
Multivariate Analysis | 14 | 2018 | 12059 | 0.470 |
Why?
|
Propensity Score | 5 | 2023 | 1913 | 0.460 |
Why?
|
Radiation Injuries | 6 | 2017 | 1189 | 0.460 |
Why?
|
Cisplatin | 9 | 2023 | 1651 | 0.460 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2018 | 611 | 0.450 |
Why?
|
Radiation-Sensitizing Agents | 3 | 2024 | 350 | 0.440 |
Why?
|
Stromal Cells | 1 | 2019 | 1330 | 0.430 |
Why?
|
Postoperative Care | 3 | 2018 | 1468 | 0.420 |
Why?
|
Lymphatic Metastasis | 7 | 2018 | 2915 | 0.420 |
Why?
|
Survival Rate | 11 | 2019 | 12725 | 0.400 |
Why?
|
Cadherins | 5 | 2001 | 903 | 0.390 |
Why?
|
Program Evaluation | 3 | 2022 | 2495 | 0.390 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 11742 | 0.390 |
Why?
|
Neoplasms, Hormone-Dependent | 2 | 2014 | 410 | 0.380 |
Why?
|
Faculty, Medical | 2 | 2022 | 1203 | 0.380 |
Why?
|
Evidence-Based Medicine | 8 | 2019 | 3688 | 0.380 |
Why?
|
Time Factors | 24 | 2024 | 39967 | 0.370 |
Why?
|
Radiation Tolerance | 5 | 2016 | 479 | 0.370 |
Why?
|
Retrospective Studies | 37 | 2024 | 80636 | 0.370 |
Why?
|
Patient Care Management | 1 | 2013 | 302 | 0.340 |
Why?
|
Cardiovascular Diseases | 4 | 2024 | 15500 | 0.330 |
Why?
|
Aged, 80 and over | 29 | 2024 | 58976 | 0.330 |
Why?
|
Male Urogenital Diseases | 1 | 2009 | 48 | 0.330 |
Why?
|
Survivors | 2 | 2017 | 2371 | 0.320 |
Why?
|
Relative Biological Effectiveness | 5 | 2017 | 312 | 0.320 |
Why?
|
Immunotherapy | 5 | 2023 | 4652 | 0.320 |
Why?
|
Urology | 3 | 2023 | 400 | 0.310 |
Why?
|
Evidence-Based Practice | 1 | 2013 | 495 | 0.310 |
Why?
|
Referral and Consultation | 4 | 2014 | 3600 | 0.310 |
Why?
|
Epidemics | 1 | 2014 | 512 | 0.310 |
Why?
|
Follow-Up Studies | 18 | 2024 | 39106 | 0.310 |
Why?
|
Patient Care Team | 3 | 2018 | 2521 | 0.300 |
Why?
|
Cost-Benefit Analysis | 2 | 2019 | 5492 | 0.300 |
Why?
|
Growth Substances | 3 | 1999 | 768 | 0.300 |
Why?
|
Hydrogels | 3 | 2023 | 720 | 0.290 |
Why?
|
Social Class | 1 | 2016 | 2004 | 0.290 |
Why?
|
Insurance, Health | 2 | 2016 | 2498 | 0.280 |
Why?
|
Female | 55 | 2024 | 392644 | 0.280 |
Why?
|
Delivery of Health Care | 2 | 2015 | 5336 | 0.270 |
Why?
|
Odds Ratio | 8 | 2016 | 9646 | 0.270 |
Why?
|
Interdisciplinary Communication | 1 | 2012 | 931 | 0.270 |
Why?
|
Pelvis | 3 | 2020 | 732 | 0.260 |
Why?
|
Prognosis | 13 | 2024 | 29625 | 0.260 |
Why?
|
Capacity Building | 3 | 2019 | 258 | 0.260 |
Why?
|
Neoplasms, Second Primary | 2 | 2023 | 1052 | 0.250 |
Why?
|
Mucins | 2 | 1999 | 568 | 0.250 |
Why?
|
Hormones | 3 | 2023 | 869 | 0.240 |
Why?
|
Mentors | 2 | 2022 | 661 | 0.240 |
Why?
|
Boston | 5 | 2017 | 9326 | 0.240 |
Why?
|
Body Mass Index | 6 | 2014 | 12953 | 0.230 |
Why?
|
Guideline Adherence | 2 | 2013 | 2220 | 0.230 |
Why?
|
Risk Factors | 20 | 2023 | 74206 | 0.230 |
Why?
|
Hodgkin Disease | 2 | 2022 | 1378 | 0.220 |
Why?
|
Randomized Controlled Trials as Topic | 12 | 2022 | 10209 | 0.220 |
Why?
|
Health Services Accessibility | 3 | 2016 | 5440 | 0.220 |
Why?
|
United States | 23 | 2023 | 72334 | 0.210 |
Why?
|
Muscle Proteins | 2 | 1999 | 1154 | 0.210 |
Why?
|
Health Care Costs | 2 | 2013 | 3242 | 0.210 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2005 | 361 | 0.210 |
Why?
|
Ataxia Telangiectasia | 1 | 2023 | 107 | 0.210 |
Why?
|
Prospective Studies | 17 | 2023 | 54425 | 0.210 |
Why?
|
Neuropeptides | 2 | 1999 | 944 | 0.210 |
Why?
|
Fiducial Markers | 2 | 2021 | 132 | 0.210 |
Why?
|
Deoxycytidine | 2 | 2018 | 877 | 0.200 |
Why?
|
HIV Infections | 7 | 2024 | 17351 | 0.200 |
Why?
|
Databases, Factual | 9 | 2019 | 7967 | 0.200 |
Why?
|
Adult | 29 | 2024 | 221177 | 0.200 |
Why?
|
Consensus | 6 | 2023 | 3123 | 0.200 |
Why?
|
Neoplasm Metastasis | 6 | 2021 | 4915 | 0.200 |
Why?
|
Kidney Neoplasms | 2 | 2020 | 4249 | 0.200 |
Why?
|
Dose-Response Relationship, Radiation | 3 | 2016 | 882 | 0.190 |
Why?
|
Logistic Models | 7 | 2016 | 13255 | 0.190 |
Why?
|
Radiosurgery | 2 | 2024 | 1342 | 0.190 |
Why?
|
Cyclobutanes | 1 | 2021 | 57 | 0.190 |
Why?
|
Carboxylic Acids | 1 | 2021 | 90 | 0.180 |
Why?
|
Data Mining | 2 | 2016 | 551 | 0.180 |
Why?
|
Gastrointestinal Diseases | 1 | 2009 | 1200 | 0.180 |
Why?
|
Disease Management | 5 | 2019 | 2508 | 0.180 |
Why?
|
Registries | 4 | 2021 | 8224 | 0.180 |
Why?
|
Muscle, Smooth | 2 | 2014 | 926 | 0.180 |
Why?
|
Polymorphism, Single-Stranded Conformational | 2 | 2001 | 329 | 0.170 |
Why?
|
Endometriosis | 2 | 2005 | 870 | 0.170 |
Why?
|
Uterine Cervical Neoplasms | 4 | 2016 | 2020 | 0.170 |
Why?
|
Radiation Dosage | 4 | 2020 | 1958 | 0.170 |
Why?
|
Incidence | 8 | 2023 | 21353 | 0.170 |
Why?
|
Patient Selection | 6 | 2018 | 4244 | 0.160 |
Why?
|
DNA Repair | 3 | 2023 | 2045 | 0.160 |
Why?
|
Rectal Diseases | 1 | 2020 | 143 | 0.160 |
Why?
|
Digestive System Physiological Phenomena | 1 | 1998 | 15 | 0.160 |
Why?
|
Cohort Studies | 14 | 2023 | 41487 | 0.160 |
Why?
|
Seminal Vesicles | 5 | 2021 | 103 | 0.160 |
Why?
|
Carcinoma, Renal Cell | 1 | 2014 | 3164 | 0.160 |
Why?
|
Tyrphostins | 1 | 1998 | 63 | 0.150 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2023 | 491 | 0.150 |
Why?
|
Nomograms | 3 | 2021 | 230 | 0.150 |
Why?
|
Cell Adhesion | 4 | 1999 | 3087 | 0.150 |
Why?
|
Phthalazines | 2 | 2018 | 383 | 0.150 |
Why?
|
Antibodies, Monoclonal | 1 | 2015 | 9177 | 0.150 |
Why?
|
Disease Progression | 6 | 2023 | 13506 | 0.150 |
Why?
|
Quality of Health Care | 1 | 2013 | 4330 | 0.150 |
Why?
|
Antineoplastic Agents | 10 | 2023 | 13639 | 0.150 |
Why?
|
Cyclonic Storms | 1 | 2019 | 116 | 0.150 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2017 | 942 | 0.150 |
Why?
|
Urination Disorders | 2 | 2016 | 238 | 0.150 |
Why?
|
Treatment Failure | 5 | 2016 | 2645 | 0.140 |
Why?
|
Urogenital Neoplasms | 1 | 2018 | 131 | 0.140 |
Why?
|
Africa South of the Sahara | 2 | 2021 | 744 | 0.140 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2024 | 1092 | 0.140 |
Why?
|
Kallikreins | 2 | 2015 | 220 | 0.140 |
Why?
|
Internationality | 2 | 2020 | 1001 | 0.140 |
Why?
|
DNA Breaks, Double-Stranded | 3 | 2018 | 612 | 0.140 |
Why?
|
Posters as Topic | 1 | 2016 | 6 | 0.140 |
Why?
|
Folklore | 1 | 2016 | 7 | 0.140 |
Why?
|
Consensus Development Conferences, NIH as Topic | 1 | 2016 | 29 | 0.140 |
Why?
|
Hospitals, Community | 2 | 2016 | 365 | 0.140 |
Why?
|
Survival Analysis | 6 | 2019 | 10090 | 0.140 |
Why?
|
Colonic Neoplasms | 2 | 1999 | 2538 | 0.130 |
Why?
|
Medicine in Literature | 1 | 2016 | 32 | 0.130 |
Why?
|
Androstenes | 1 | 2018 | 181 | 0.130 |
Why?
|
Career Mobility | 1 | 2018 | 259 | 0.130 |
Why?
|
Peptides | 2 | 1999 | 4358 | 0.130 |
Why?
|
Radium | 1 | 2016 | 72 | 0.130 |
Why?
|
Regression Analysis | 5 | 2018 | 6343 | 0.130 |
Why?
|
Recombinases | 1 | 2016 | 67 | 0.130 |
Why?
|
Cytoskeletal Proteins | 2 | 1998 | 1342 | 0.130 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2023 | 946 | 0.130 |
Why?
|
SEER Program | 6 | 2016 | 1450 | 0.120 |
Why?
|
Risk Assessment | 6 | 2016 | 23995 | 0.120 |
Why?
|
Information Management | 1 | 2015 | 100 | 0.120 |
Why?
|
Administration, Intravesical | 3 | 2023 | 92 | 0.120 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2019 | 339 | 0.120 |
Why?
|
Clinical Trials as Topic | 4 | 2023 | 8002 | 0.120 |
Why?
|
RNA, Neoplasm | 1 | 2018 | 750 | 0.120 |
Why?
|
Hematuria | 1 | 2016 | 233 | 0.120 |
Why?
|
Sulfonamides | 1 | 2005 | 1978 | 0.120 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 2273 | 0.120 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 2014 | 2199 | 0.120 |
Why?
|
Urinary Diversion | 1 | 2015 | 134 | 0.120 |
Why?
|
Ifosfamide | 1 | 2015 | 232 | 0.120 |
Why?
|
Statistics, Nonparametric | 3 | 2016 | 2850 | 0.120 |
Why?
|
Forefoot, Human | 1 | 2014 | 31 | 0.120 |
Why?
|
Carboplatin | 2 | 2015 | 794 | 0.120 |
Why?
|
Fanconi Anemia Complementation Group D2 Protein | 1 | 2015 | 146 | 0.120 |
Why?
|
Mitomycin | 1 | 2015 | 263 | 0.120 |
Why?
|
Hospitals, Teaching | 2 | 2016 | 1156 | 0.120 |
Why?
|
Pyrazoles | 1 | 2005 | 2009 | 0.120 |
Why?
|
Practice Guidelines as Topic | 5 | 2019 | 7390 | 0.120 |
Why?
|
Condylomata Acuminata | 1 | 2014 | 75 | 0.120 |
Why?
|
Medicaid | 3 | 2016 | 2818 | 0.110 |
Why?
|
Fluorouracil | 2 | 2018 | 1641 | 0.110 |
Why?
|
Penis | 4 | 2018 | 212 | 0.110 |
Why?
|
Community Health Centers | 1 | 2017 | 461 | 0.110 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2021 | 1374 | 0.110 |
Why?
|
Uterine Cervical Diseases | 1 | 2014 | 73 | 0.110 |
Why?
|
Predictive Value of Tests | 5 | 2018 | 15266 | 0.110 |
Why?
|
DNA Methylation | 3 | 2023 | 4398 | 0.110 |
Why?
|
Vascular Endothelial Growth Factor B | 1 | 2013 | 26 | 0.110 |
Why?
|
Urologic Diseases | 1 | 2016 | 247 | 0.110 |
Why?
|
Cost Savings | 1 | 2019 | 913 | 0.110 |
Why?
|
Vaginal Neoplasms | 1 | 2014 | 104 | 0.110 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2019 | 5315 | 0.110 |
Why?
|
Medically Uninsured | 2 | 2016 | 836 | 0.110 |
Why?
|
Age Factors | 9 | 2022 | 18395 | 0.110 |
Why?
|
Universities | 1 | 2018 | 993 | 0.110 |
Why?
|
Comparative Effectiveness Research | 1 | 2018 | 709 | 0.110 |
Why?
|
Disasters | 1 | 2019 | 519 | 0.110 |
Why?
|
Equipment and Supplies | 1 | 2015 | 273 | 0.110 |
Why?
|
Interinstitutional Relations | 1 | 2014 | 236 | 0.110 |
Why?
|
Endonucleases | 1 | 2016 | 371 | 0.110 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2016 | 357 | 0.110 |
Why?
|
Uterine Hemorrhage | 1 | 2014 | 240 | 0.100 |
Why?
|
Biopsy | 4 | 2023 | 6766 | 0.100 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2015 | 718 | 0.100 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2016 | 592 | 0.100 |
Why?
|
Penile Neoplasms | 1 | 2014 | 161 | 0.100 |
Why?
|
Quality Assurance, Health Care | 2 | 2013 | 2169 | 0.100 |
Why?
|
Medicare | 3 | 2022 | 6770 | 0.100 |
Why?
|
Movement | 3 | 2015 | 1478 | 0.100 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2015 | 495 | 0.100 |
Why?
|
Database Management Systems | 1 | 2013 | 257 | 0.100 |
Why?
|
Intestinal Diseases | 1 | 2016 | 504 | 0.100 |
Why?
|
Molecular Imaging | 1 | 2018 | 815 | 0.100 |
Why?
|
Radiometry | 2 | 2017 | 813 | 0.100 |
Why?
|
Minority Groups | 2 | 2016 | 1203 | 0.100 |
Why?
|
Trans-Activators | 2 | 1998 | 2856 | 0.100 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 1405 | 0.090 |
Why?
|
Costs and Cost Analysis | 2 | 2016 | 1668 | 0.090 |
Why?
|
Research Design | 3 | 2023 | 6180 | 0.090 |
Why?
|
Marital Status | 1 | 2012 | 426 | 0.090 |
Why?
|
Androgens | 3 | 2023 | 1286 | 0.090 |
Why?
|
DNA Damage | 2 | 2023 | 2446 | 0.090 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2015 | 474 | 0.090 |
Why?
|
Interferon-gamma | 1 | 2019 | 3162 | 0.090 |
Why?
|
Piperazines | 2 | 2018 | 2523 | 0.090 |
Why?
|
Consumer Health Information | 1 | 2012 | 215 | 0.090 |
Why?
|
Advisory Committees | 1 | 2014 | 787 | 0.090 |
Why?
|
Reactive Oxygen Species | 1 | 2018 | 2141 | 0.090 |
Why?
|
Mammography | 1 | 2021 | 2430 | 0.080 |
Why?
|
Carcinoma, Ductal | 1 | 2010 | 97 | 0.080 |
Why?
|
Quality Indicators, Health Care | 1 | 2019 | 1792 | 0.080 |
Why?
|
Patient-Centered Care | 1 | 2019 | 1421 | 0.080 |
Why?
|
Genomics | 5 | 2023 | 5821 | 0.080 |
Why?
|
ras Proteins | 1 | 2014 | 1054 | 0.080 |
Why?
|
Nephrectomy | 1 | 2014 | 937 | 0.080 |
Why?
|
Intestines | 2 | 2022 | 1909 | 0.080 |
Why?
|
BRCA1 Protein | 1 | 2015 | 1155 | 0.080 |
Why?
|
History, 20th Century | 1 | 2016 | 2767 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2018 | 2917 | 0.080 |
Why?
|
Terminology as Topic | 1 | 2015 | 1530 | 0.080 |
Why?
|
Uncertainty | 1 | 2013 | 754 | 0.080 |
Why?
|
Diphosphonates | 1 | 2013 | 636 | 0.070 |
Why?
|
Gastrins | 2 | 1998 | 74 | 0.070 |
Why?
|
Lymphocyte Activation | 1 | 2019 | 5486 | 0.070 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2012 | 549 | 0.070 |
Why?
|
Physicians | 2 | 2017 | 4591 | 0.070 |
Why?
|
Adjuvants, Immunologic | 2 | 2023 | 1036 | 0.070 |
Why?
|
Multicenter Studies as Topic | 3 | 2022 | 1702 | 0.070 |
Why?
|
Lung Neoplasms | 3 | 2019 | 13380 | 0.070 |
Why?
|
Perioperative Care | 1 | 2015 | 1033 | 0.070 |
Why?
|
Quality Improvement | 2 | 2013 | 3801 | 0.070 |
Why?
|
Homeostasis | 1 | 1998 | 3323 | 0.070 |
Why?
|
Risk | 2 | 2019 | 9610 | 0.070 |
Why?
|
Gene Expression Profiling | 2 | 2020 | 9420 | 0.070 |
Why?
|
Organ Size | 3 | 2020 | 2254 | 0.070 |
Why?
|
Imidazoles | 1 | 2013 | 1180 | 0.070 |
Why?
|
Massachusetts | 2 | 2017 | 8830 | 0.070 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2018 | 2790 | 0.070 |
Why?
|
Epithelial Cells | 1 | 1998 | 3673 | 0.070 |
Why?
|
Cross-Sectional Studies | 4 | 2023 | 26125 | 0.070 |
Why?
|
Population Surveillance | 1 | 2016 | 2598 | 0.070 |
Why?
|
Medical Informatics | 1 | 2013 | 733 | 0.060 |
Why?
|
Cobalt Radioisotopes | 2 | 2016 | 75 | 0.060 |
Why?
|
Neoplasm Proteins | 1 | 1998 | 3617 | 0.060 |
Why?
|
Mutation | 8 | 2024 | 30052 | 0.060 |
Why?
|
Patient Education as Topic | 2 | 2012 | 2319 | 0.060 |
Why?
|
Bone Density Conservation Agents | 1 | 2013 | 795 | 0.060 |
Why?
|
Obesity | 1 | 2007 | 12947 | 0.060 |
Why?
|
Africa | 2 | 2019 | 709 | 0.060 |
Why?
|
Breast Neoplasms | 2 | 2024 | 21012 | 0.060 |
Why?
|
Endostatins | 1 | 2005 | 168 | 0.060 |
Why?
|
Gene Expression Regulation, Neoplastic | 6 | 2018 | 8547 | 0.060 |
Why?
|
Particle Size | 1 | 2009 | 1648 | 0.060 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2010 | 710 | 0.060 |
Why?
|
Cost of Illness | 1 | 2015 | 1936 | 0.060 |
Why?
|
Rad51 Recombinase | 2 | 2016 | 189 | 0.060 |
Why?
|
Neovascularization, Physiologic | 1 | 2012 | 1349 | 0.060 |
Why?
|
Linear Energy Transfer | 2 | 2016 | 152 | 0.060 |
Why?
|
Nitriles | 2 | 2021 | 971 | 0.060 |
Why?
|
Technology, Radiologic | 2 | 2016 | 160 | 0.060 |
Why?
|
Comorbidity | 3 | 2016 | 10508 | 0.060 |
Why?
|
Pilot Projects | 2 | 2017 | 8631 | 0.060 |
Why?
|
Weight Gain | 1 | 2014 | 2348 | 0.060 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 1 | 2023 | 106 | 0.060 |
Why?
|
Femur Head | 2 | 2018 | 297 | 0.050 |
Why?
|
Young Adult | 5 | 2020 | 59243 | 0.050 |
Why?
|
Biomedical Research | 2 | 2015 | 3429 | 0.050 |
Why?
|
Testosterone | 1 | 2014 | 2472 | 0.050 |
Why?
|
Fanconi Anemia | 2 | 2016 | 324 | 0.050 |
Why?
|
Animals | 12 | 2023 | 168459 | 0.050 |
Why?
|
Overweight | 1 | 2014 | 2417 | 0.050 |
Why?
|
Patient Participation | 1 | 2012 | 1444 | 0.050 |
Why?
|
MicroRNAs | 1 | 2018 | 3816 | 0.050 |
Why?
|
Tumor Cells, Cultured | 3 | 1999 | 6132 | 0.050 |
Why?
|
Longitudinal Studies | 1 | 2018 | 14605 | 0.050 |
Why?
|
Papillomavirus Infections | 1 | 2014 | 1613 | 0.050 |
Why?
|
Chromatin | 1 | 2014 | 2960 | 0.050 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2023 | 426 | 0.050 |
Why?
|
alpha Catenin | 2 | 1998 | 37 | 0.050 |
Why?
|
Patient Compliance | 1 | 2012 | 2690 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4511 | 0.050 |
Why?
|
Societies, Medical | 3 | 2019 | 3905 | 0.050 |
Why?
|
Radiography | 4 | 2015 | 6965 | 0.050 |
Why?
|
Desmoplakins | 2 | 1998 | 61 | 0.050 |
Why?
|
Liver Regeneration | 1 | 2003 | 213 | 0.050 |
Why?
|
T-Lymphocytes | 1 | 2019 | 10194 | 0.050 |
Why?
|
Tosyl Compounds | 1 | 2021 | 115 | 0.050 |
Why?
|
Fertility | 1 | 2005 | 771 | 0.050 |
Why?
|
Patient Satisfaction | 1 | 2013 | 3461 | 0.040 |
Why?
|
Cell Line, Tumor | 5 | 2018 | 16981 | 0.040 |
Why?
|
Internet | 1 | 2012 | 3092 | 0.040 |
Why?
|
Frameshift Mutation | 2 | 1999 | 392 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2023 | 36426 | 0.040 |
Why?
|
Decision Support Techniques | 1 | 2010 | 1998 | 0.040 |
Why?
|
Colorectal Neoplasms | 4 | 2001 | 6935 | 0.040 |
Why?
|
Hepatectomy | 1 | 2003 | 557 | 0.040 |
Why?
|
Data Collection | 2 | 2021 | 3322 | 0.040 |
Why?
|
BK Virus | 1 | 2020 | 123 | 0.040 |
Why?
|
Analysis of Variance | 1 | 2008 | 6228 | 0.040 |
Why?
|
Genes, APC | 1 | 1999 | 145 | 0.040 |
Why?
|
Lymph Node Excision | 2 | 2017 | 1271 | 0.040 |
Why?
|
Software | 1 | 2013 | 4434 | 0.040 |
Why?
|
Base Pairing | 1 | 1999 | 140 | 0.040 |
Why?
|
Recombinant Proteins | 2 | 1999 | 6534 | 0.040 |
Why?
|
DNA-Binding Proteins | 1 | 2016 | 9606 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2021 | 15631 | 0.040 |
Why?
|
Enterochromaffin-like Cells | 1 | 1998 | 4 | 0.040 |
Why?
|
Tumor Burden | 2 | 2015 | 1893 | 0.040 |
Why?
|
Area Under Curve | 2 | 2013 | 1638 | 0.040 |
Why?
|
Polyomavirus Infections | 1 | 2020 | 194 | 0.040 |
Why?
|
Receptors, Cholecystokinin | 1 | 1997 | 18 | 0.040 |
Why?
|
Enterochromaffin Cells | 1 | 1997 | 12 | 0.040 |
Why?
|
Anilides | 1 | 2021 | 411 | 0.040 |
Why?
|
Mice | 7 | 2023 | 81525 | 0.040 |
Why?
|
Cell Transformation, Neoplastic | 2 | 1998 | 2825 | 0.040 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2015 | 9000 | 0.040 |
Why?
|
Adenomatous Polyposis Coli | 1 | 1999 | 218 | 0.040 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 1999 | 302 | 0.040 |
Why?
|
Patient Preference | 2 | 2017 | 924 | 0.040 |
Why?
|
Colitis, Ulcerative | 2 | 2001 | 1922 | 0.040 |
Why?
|
Tumor Virus Infections | 1 | 2020 | 438 | 0.040 |
Why?
|
Apoptosis | 4 | 2015 | 9486 | 0.040 |
Why?
|
Cell Compartmentation | 1 | 1998 | 384 | 0.040 |
Why?
|
Stomach Neoplasms | 2 | 1998 | 1459 | 0.040 |
Why?
|
Adenomatous Polyposis Coli Protein | 1 | 1998 | 181 | 0.040 |
Why?
|
Injections | 1 | 2020 | 830 | 0.040 |
Why?
|
Child | 2 | 2022 | 80153 | 0.030 |
Why?
|
Cell Survival | 2 | 2018 | 5791 | 0.030 |
Why?
|
Cell Movement | 2 | 2018 | 5203 | 0.030 |
Why?
|
Health Physics | 1 | 2016 | 32 | 0.030 |
Why?
|
Cesium Radioisotopes | 1 | 2016 | 38 | 0.030 |
Why?
|
Exons | 2 | 1999 | 2391 | 0.030 |
Why?
|
Brain Neoplasms | 1 | 2017 | 9031 | 0.030 |
Why?
|
Introns | 1 | 1999 | 981 | 0.030 |
Why?
|
beta Catenin | 2 | 1998 | 1040 | 0.030 |
Why?
|
Fibroblast Growth Factor 2 | 2 | 2012 | 592 | 0.030 |
Why?
|
Hospitals, Veterans | 1 | 2018 | 395 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 5 | 2021 | 20570 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2022 | 2571 | 0.030 |
Why?
|
Mass Screening | 2 | 2022 | 5428 | 0.030 |
Why?
|
Hot Temperature | 1 | 2022 | 1440 | 0.030 |
Why?
|
Angiogenesis Inhibitors | 1 | 2005 | 2047 | 0.030 |
Why?
|
Genes, p53 | 1 | 1998 | 712 | 0.030 |
Why?
|
Organizations, Nonprofit | 1 | 2015 | 105 | 0.030 |
Why?
|
Endodeoxyribonucleases | 1 | 2016 | 164 | 0.030 |
Why?
|
Adolescent | 4 | 2020 | 88319 | 0.030 |
Why?
|
Sequence Deletion | 1 | 1999 | 1494 | 0.030 |
Why?
|
Proteus mirabilis | 1 | 2014 | 24 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2022 | 2330 | 0.030 |
Why?
|
Protein Kinase C-alpha | 1 | 2014 | 113 | 0.030 |
Why?
|
Integrins | 1 | 1998 | 834 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2018 | 736 | 0.030 |
Why?
|
Immunohistochemistry | 4 | 2019 | 11076 | 0.030 |
Why?
|
Point Mutation | 1 | 1999 | 1595 | 0.030 |
Why?
|
Coitus | 1 | 2014 | 132 | 0.030 |
Why?
|
Decision Making | 2 | 2018 | 3929 | 0.030 |
Why?
|
Kinetics | 1 | 2021 | 6374 | 0.030 |
Why?
|
Meta-Analysis as Topic | 1 | 2018 | 1380 | 0.030 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2011 | 1116 | 0.030 |
Why?
|
Sample Size | 1 | 2016 | 841 | 0.030 |
Why?
|
Sex Factors | 2 | 2019 | 10552 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2021 | 1664 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor C | 1 | 2013 | 127 | 0.030 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2016 | 793 | 0.030 |
Why?
|
Cell Proliferation | 2 | 2018 | 10445 | 0.030 |
Why?
|
Mice, Nude | 1 | 1999 | 3615 | 0.030 |
Why?
|
Aftercare | 1 | 2018 | 914 | 0.030 |
Why?
|
Calibration | 1 | 2015 | 818 | 0.020 |
Why?
|
Inflammation | 1 | 2012 | 10773 | 0.020 |
Why?
|
Mice, Inbred C57BL | 3 | 2005 | 22169 | 0.020 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2014 | 629 | 0.020 |
Why?
|
Observer Variation | 1 | 2018 | 2606 | 0.020 |
Why?
|
DNA Replication | 1 | 1999 | 1418 | 0.020 |
Why?
|
Research Personnel | 1 | 2016 | 588 | 0.020 |
Why?
|
Triage | 1 | 2018 | 986 | 0.020 |
Why?
|
Diffusion of Innovation | 1 | 2016 | 728 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 2020 | 4806 | 0.020 |
Why?
|
Credentialing | 1 | 2012 | 116 | 0.020 |
Why?
|
Qualitative Research | 2 | 2012 | 3023 | 0.020 |
Why?
|
Hydronephrosis | 1 | 2013 | 271 | 0.020 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2018 | 1651 | 0.020 |
Why?
|
Receptors, Androgen | 1 | 2018 | 1079 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2021 | 2651 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 1999 | 1961 | 0.020 |
Why?
|
Vaginal Smears | 1 | 2014 | 499 | 0.020 |
Why?
|
Proctitis | 1 | 2011 | 41 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 1999 | 1858 | 0.020 |
Why?
|
Pandemics | 2 | 2022 | 8654 | 0.020 |
Why?
|
Bleomycin | 1 | 2012 | 494 | 0.020 |
Why?
|
Transfection | 1 | 1999 | 5774 | 0.020 |
Why?
|
Palladium | 1 | 2011 | 67 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2021 | 5247 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 1999 | 2385 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 3877 | 0.020 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2012 | 297 | 0.020 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2014 | 857 | 0.020 |
Why?
|
Etoposide | 1 | 2012 | 634 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2016 | 1258 | 0.020 |
Why?
|
Cervix Uteri | 1 | 2014 | 570 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2019 | 20098 | 0.020 |
Why?
|
Colic | 1 | 2010 | 44 | 0.020 |
Why?
|
Lymphatic Diseases | 1 | 2012 | 320 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2016 | 3416 | 0.020 |
Why?
|
Altruism | 1 | 2012 | 208 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 2015 | 1008 | 0.020 |
Why?
|
Chemokine CXCL12 | 1 | 2012 | 454 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2023 | 3802 | 0.020 |
Why?
|
Radioisotopes | 1 | 2011 | 499 | 0.020 |
Why?
|
Immobilization | 1 | 2010 | 229 | 0.020 |
Why?
|
Up-Regulation | 1 | 2018 | 4124 | 0.020 |
Why?
|
Cell Cycle | 1 | 2018 | 2932 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2001 | 5789 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2020 | 2639 | 0.020 |
Why?
|
Regeneration | 1 | 1998 | 1511 | 0.020 |
Why?
|
DNA | 1 | 2023 | 7212 | 0.020 |
Why?
|
Morbidity | 1 | 2015 | 1750 | 0.020 |
Why?
|
Models, Genetic | 1 | 1999 | 3442 | 0.020 |
Why?
|
Prostheses and Implants | 1 | 2016 | 1271 | 0.020 |
Why?
|
Rotation | 1 | 2010 | 517 | 0.020 |
Why?
|
Interleukin-8 | 1 | 2012 | 695 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2023 | 3530 | 0.020 |
Why?
|
Benzimidazoles | 1 | 2014 | 858 | 0.020 |
Why?
|
Vagina | 1 | 2014 | 838 | 0.020 |
Why?
|
Defecation | 1 | 2010 | 190 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 558 | 0.020 |
Why?
|
Benchmarking | 1 | 2015 | 1045 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 1999 | 4243 | 0.020 |
Why?
|
Homeodomain Proteins | 1 | 2018 | 2416 | 0.020 |
Why?
|
Pelvic Bones | 1 | 2010 | 270 | 0.020 |
Why?
|
Muridae | 2 | 1998 | 56 | 0.020 |
Why?
|
Reference Values | 1 | 2015 | 4920 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2022 | 3201 | 0.020 |
Why?
|
Erectile Dysfunction | 1 | 2011 | 444 | 0.020 |
Why?
|
Quinazolines | 1 | 2014 | 1371 | 0.020 |
Why?
|
Iodine Radioisotopes | 1 | 2011 | 1031 | 0.020 |
Why?
|
Subcutaneous Fat | 1 | 2010 | 393 | 0.020 |
Why?
|
Information Dissemination | 1 | 2015 | 1126 | 0.020 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 1998 | 3612 | 0.020 |
Why?
|
Computational Biology | 1 | 2019 | 3518 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2018 | 22176 | 0.020 |
Why?
|
California | 1 | 2011 | 1429 | 0.020 |
Why?
|
Reimbursement, Incentive | 1 | 2012 | 543 | 0.020 |
Why?
|
Histamine H2 Antagonists | 2 | 1998 | 166 | 0.020 |
Why?
|
Phantoms, Imaging | 1 | 2015 | 2526 | 0.020 |
Why?
|
Interleukin-1beta | 1 | 2012 | 999 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1745 | 0.020 |
Why?
|
Pseudomonas aeruginosa | 1 | 2014 | 1277 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2020 | 12341 | 0.020 |
Why?
|
Linear Models | 1 | 2016 | 5871 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10766 | 0.020 |
Why?
|
Crohn Disease | 1 | 1998 | 2279 | 0.020 |
Why?
|
Protein Binding | 1 | 1998 | 9351 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2014 | 3602 | 0.020 |
Why?
|
Acute Disease | 1 | 2016 | 7237 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2005 | 18252 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2016 | 5869 | 0.020 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2018 | 3357 | 0.020 |
Why?
|
Kidney Transplantation | 1 | 2020 | 4234 | 0.020 |
Why?
|
Contrast Media | 1 | 2018 | 5311 | 0.020 |
Why?
|
Mitochondria | 1 | 2018 | 3624 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2008 | 12148 | 0.010 |
Why?
|
Growth Inhibitors | 1 | 2005 | 378 | 0.010 |
Why?
|
Femur | 1 | 2010 | 1307 | 0.010 |
Why?
|
Genetic Variation | 1 | 1999 | 6567 | 0.010 |
Why?
|
Abdominal Pain | 1 | 2010 | 1071 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2015 | 2811 | 0.010 |
Why?
|
Body Weight | 1 | 2014 | 4618 | 0.010 |
Why?
|
Diarrhea | 1 | 2010 | 1318 | 0.010 |
Why?
|
Cyclohexanes | 1 | 2003 | 152 | 0.010 |
Why?
|
Residence Characteristics | 1 | 2012 | 2093 | 0.010 |
Why?
|
Cell Adhesion Molecules | 2 | 1999 | 1600 | 0.010 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 2003 | 283 | 0.010 |
Why?
|
Triazoles | 2 | 1998 | 903 | 0.010 |
Why?
|
Sesquiterpenes | 1 | 2003 | 176 | 0.010 |
Why?
|
Motivation | 1 | 2012 | 2006 | 0.010 |
Why?
|
Health Policy | 1 | 2014 | 2684 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2012 | 3208 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2018 | 7856 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2012 | 3492 | 0.010 |
Why?
|
Laparoscopy | 1 | 2012 | 2035 | 0.010 |
Why?
|
Endothelium | 1 | 2003 | 765 | 0.010 |
Why?
|
Mice, SCID | 1 | 2005 | 2626 | 0.010 |
Why?
|
Blotting, Western | 2 | 1998 | 5035 | 0.010 |
Why?
|
Polymerase Chain Reaction | 2 | 2001 | 6075 | 0.010 |
Why?
|
Cause of Death | 1 | 2010 | 3683 | 0.010 |
Why?
|
gamma Catenin | 1 | 1998 | 44 | 0.010 |
Why?
|
Catenins | 1 | 1998 | 44 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2014 | 12974 | 0.010 |
Why?
|
Fibromatosis, Aggressive | 1 | 1999 | 126 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2016 | 15842 | 0.010 |
Why?
|
Microcirculation | 1 | 2003 | 1273 | 0.010 |
Why?
|
Codon | 1 | 1999 | 601 | 0.010 |
Why?
|
Recurrence | 1 | 2010 | 8465 | 0.010 |
Why?
|
Phosphoserine | 1 | 1997 | 203 | 0.010 |
Why?
|
Blotting, Southern | 1 | 1998 | 777 | 0.010 |
Why?
|
Phosphotyrosine | 1 | 1997 | 456 | 0.010 |
Why?
|
Hepatocytes | 1 | 2003 | 1233 | 0.010 |
Why?
|
HIV-1 | 1 | 2013 | 6863 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 1998 | 1705 | 0.010 |
Why?
|
Lung | 1 | 2014 | 10000 | 0.010 |
Why?
|
Family Health | 1 | 1999 | 1257 | 0.010 |
Why?
|
Epithelium | 1 | 1998 | 1603 | 0.010 |
Why?
|
DNA Primers | 1 | 1998 | 2819 | 0.010 |
Why?
|
Random Allocation | 1 | 1998 | 2395 | 0.010 |
Why?
|
RNA, Messenger | 2 | 1998 | 12795 | 0.010 |
Why?
|
Gene Frequency | 1 | 1999 | 3606 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 1998 | 1745 | 0.010 |
Why?
|
Gene Deletion | 1 | 1999 | 2665 | 0.010 |
Why?
|
Cell Division | 1 | 1999 | 4465 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 1999 | 4111 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 1998 | 4575 | 0.010 |
Why?
|
Colon | 1 | 1998 | 1792 | 0.010 |
Why?
|
Phosphoproteins | 1 | 1998 | 2448 | 0.010 |
Why?
|
Adenoma | 1 | 1999 | 2160 | 0.000 |
Why?
|
Base Sequence | 1 | 1999 | 12441 | 0.000 |
Why?
|
Alleles | 1 | 1999 | 6863 | 0.000 |
Why?
|
Gene Expression | 1 | 2001 | 7581 | 0.000 |
Why?
|
Liver | 1 | 2003 | 7529 | 0.000 |
Why?
|
Phosphorylation | 1 | 1997 | 8320 | 0.000 |
Why?
|
Amino Acid Sequence | 1 | 1998 | 13446 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1998 | 17635 | 0.000 |
Why?
|
Pregnancy | 1 | 2005 | 29874 | 0.000 |
Why?
|